Tesaro Shakes Up EU PARP Market With Zejula Launches
Executive Summary
EU approval signals the start of a marketing push against the combined might of AstraZeneca and Merck & Co – Tesaro believes it has the label to set it apart. For now, at least.
You may also be interested in...
QUADRA Supports Broader Use For Tesaro's PARP Inhibitor Zejula
Study in late-line use of heavily pretreated ovarian cancer may bring labeling closer in line with competitors, yet with limited commercial impact, analysts say.
Think Positive: Clovis Confident Of CHMP Okay For Rubraca
The US biotech expects to finally get its PARP inhibitor for ovarian cancer onto the European market in the next few months to compete with rivals AstraZeneca and Tesaro after the CHMP "communicated a positive trend vote" ahead of an opinion being issued next month.
Finance Watch: Semma Raises $114m As VC Funding Keeps Up Brisk Pace
Semma closed a $114m Series B round to fund development of insulin-producing cells. Also, Tesaro and Catalyst are among recent public company financings, while Otonomy shifted gears, laying off sales staff.